A recent study reported data from a murine GBM model for an oncolytic adenovirus that infects and depletes FAP+ pericytes and GBM cells, highlighting the potential utility of oncolytic virus immunotherapy targeting FAP in GBM [10]. This evidence concerns the gene FAP and glioblastoma.